Changing the status quo

We built an online platform through which we wanted to see a change in the way healthcare was delivered to our close family members. Now we want to change the status quo.

We believe that the future of healthcare lies in precision medicine coupled with advanced digital tools, for that our goal is to enable the use of medical technologies in everyday life so that we can improve the health and wellness of our clients.

Download our Online Platform Guide.

Our DNA

We believe that revealing specific information encoded
within the DNA can help individuals take a step forward towards a personalised healthy living and have an accurate and more successful treatment and fitness regimen.

We believe that:
Genotype + Environment = Phenotype.

Physical characteristics are the result of a complex interaction between genes and environmental factors, and to make a sensible and actionable insight from Genetic information, we:

A.    Engage a qualified partner specialist whenever a clinical report is set to be sent out to one of our patients, in order to provide an accurate and actionable interpretation.

B.    Maintain the highest level of quality and privacy in our service.

C.    Communicate information in an understandable and UI friendly manner to the general public, whilst presenting information that is appropriate for further medical advice.

The Story so far..

The need

It all started with a drug complication that Rightangled’s co-founder saw first hand in her family. Floriane's relative was experiencing drug side effects and responding poorly to an anticoagulant drug. The medication was Plavix (Clopidogrel) and the side effects were gum bleeding and bruises. After seeing her relative survive 5 strokes, it was clear that the drug was not working and a personalised treatment regimen was needed.

NHS funding and support

With Abdullah's knowledge about genetics and its influence on the way we respond to drugs, he and Flo decided to make genetic information more readily available. The concept of a new service design was born, to enable the use of genetic information within the medical practice, in an accurate, streamlined and affordable way. The Heart DNA Test project was later presented to one of the NHS innovation adoption arms in the West Midlands, and it later received the backing and funding from NHS England.

Heart DNA Test launch

Heart DNA testing service was launched in mid 2017 and ever since, it has been helping private practices around London and abroad to remove patient-physician communication barriers, helping patients minimise their cardiac risks and reach their optimal treatment regimen faster, and for doctors to have a complete risk profile for their patients that is objective and evidence-based.

Fitness DNA Test launch

In early 2019, Rightangled fully launched its second specialised genetic testing service that tapped into the fitness and wellbeing markets. The new testing service expanded the company's transatlantic operations with a second branch that later opened in Austin, Texas.

Joined by our passion for health & wellbeing

Board of Directors

The Team

Laetitia Dancourt

Marketing Manager

Laetitia is a Social Media Manager at Rightangled. She has previous marketing and digital communication experiences within advertising agencies and international companies like Publicis and BNP Paribas in Paris. After an experience in New York in the meetings industry, she made her way to London to discover a new culture and face new challenges!

Ella Paoli

Operations Manager

Operations Manager at Rightangled Limited with a previous experience in the biotech and pharmaceutical industry. Having previously worked for Janssen Cilag, Novartis and Stallergenes Greer Ella was involved in developing and delivering campaigns within the medical information departments, rare diseases and batch recall crisis management.

Floriane Rousse-Marquet

Co-Founder

A researcher and service designer with a background in industrial design. Flo has over 4 years of experience working for leading design consultancies over the world, where she has provided extensive research and strategy services for leading pharmaceutical companies such as GSK and Novo Nordisk. She also worked in global development with international organisations tackling complex systems.

Abdullah Sabyah

Founder and CEO

A scientist-entrepreneur and a healthcare professional, also a member of the British Heart Foundation Alliance, a member of the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay (the patent is for a technology to detect DNA sequences in real-time).

Dr Sibtain Anwar

Non- Exec

Dr Sibtain Anwar a Senior Lecturer and Consultant in the Department of Perioperative Medicine at the Barts Heart Centre - Europe’s largest cardiovascular institution. He also sits on the Pain Medicine Council at the Royal Society of Medicine. He completed clinical training at Imperial College London, while also pursuing his research interests as an Honorary Fellow of the Academic Cardiology Unit at The National Heart and Lung Institute.

Professor Sir John Cunningham

Non-Exec

Lead Scientific Advisor, frontline NHS clinician at The Royal Free Hospital and Professor of Nephrology at UCL Medical School. Active researcher with over I00 papers published in peer reviewed journals. Honorary Fellow of Trinity Hall, University of Cambridge.

Dr Ahmed Merghani

Non-Exec

Ahmed graduated from Barts and the London Medical School in 2005, having also accomplished an intercalated BMedSci (hons) degree in Molecular Therapeutics. He attained membership of the Royal College of Physicians in 2008 and went on to achieve a National training number in Cardiology at the West Midlands Deanery. Since then, he has worked as a cardiology registrar in Birmingham and Coventry. In 2012, he pursued an MD degree at St. George’s, University of London.

Alexis Toft

Non-Exec

A former founder and MD of INEOS Healthcare which was based on the drug he invented. He raised £73mn, grew it from 3 to over 1,000 people involved working across 23 countries in 250 hospitals before exiting.